|
健保碼及健保價 |
|
See related Naglazyme inj information |
|
|
|
製造商 |
Biomarin |
|
代理/經銷商 |
TSPC |
|
成份 |
Galsulfase |
|
適應症 |
Mucopolysaccharidosis VI |
|
用量 |
1 mg/kg once weekly as as IV infusion over no < 4 hr. Pretreatment with antihistamines with or without antipyretics is recommended 30-60 mins prior to the start of the infusion. |
|
注意事項 |
Infusion reactions. eva luation of airway patency should be considered prior to initiation of treatment. Acute febrile or respiratory illness. Pregnancy, lactation. |
|
不良反應 |
Urticaria of the face and neck, bronchospasm, respiratory distress & apnea; headache, fever, arthralgia, vomiting, upper respiratory infections, abdominal pain, diarrhea, ear pain, cough & otitis media; infusion-related reactions.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Naglazyme 注射劑 |
|
Naglazyme 5 mg/5 mL x 5 mL |
|
|
|
Manufacturer: |
Biomarin |
|
Distributor: |
TSPC
|
|
|
|
